• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology.从大脑到脉管系统对β淀粉样蛋白分布进行基因改造可改善tau蛋白病变。
Brain Pathol. 2009 Jul;19(3):421-30. doi: 10.1111/j.1750-3639.2008.00194.x. Epub 2008 Jul 24.
2
Cellular cholesterol homeostasis and Alzheimer's disease.细胞胆固醇稳态与阿尔茨海默病。
J Lipid Res. 2017 Dec;58(12):2239-2254. doi: 10.1194/jlr.R075630. Epub 2017 Mar 15.
3
Thy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer's disease.Thy1-ApoE4/C/EBPβ 双转基因小鼠可作为散发性阿尔茨海默病模型。
Mol Psychiatry. 2024 Oct;29(10):3040-3055. doi: 10.1038/s41380-024-02565-x. Epub 2024 Apr 24.
4
Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.在三转基因小鼠中阻断载脂蛋白E/β-淀粉样蛋白相互作用可改善阿尔茨海默病相关的β-淀粉样蛋白和tau病理。
J Neurochem. 2014 Feb;128(4):577-91. doi: 10.1111/jnc.12484. Epub 2013 Nov 6.
5
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.在转基因小鼠中,通过基因手段增加tau蛋白水平并不能调节β淀粉样蛋白病变的发生或进展。
J Neurochem. 2007 Aug;102(4):1053-63. doi: 10.1111/j.1471-4159.2007.04607.x. Epub 2007 Apr 30.
6
Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.Aβ 诱导的阿尔茨海默病相关 tau 病理扩散加速及其与朊病毒蛋白的关系。
Acta Neuropathol. 2019 Dec;138(6):913-941. doi: 10.1007/s00401-019-02053-5. Epub 2019 Aug 14.
7
Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.阻断 apoE/Aβ 相互作用可改善 APOE ε2 和 ε4 靶向替换阿尔茨海默病模型小鼠的 Aβ 相关病理。
Acta Neuropathol Commun. 2014 Jun 28;2:75. doi: 10.1186/s40478-014-0075-0.
8
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.在淀粉样前体蛋白转基因模型中,人类载脂蛋白E4改变了β淀粉样蛋白40:42的比例,并促进了脑淀粉样血管病的形成。
J Neurosci. 2005 Mar 16;25(11):2803-10. doi: 10.1523/JNEUROSCI.5170-04.2005.
9
Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-β immunoreactivity after traumatic brain injury in 3xTG-AD mice.人载脂蛋白 E4 加重创伤性脑损伤后 3xTg-AD 小鼠的急性轴索病变,但不加重淀粉样-β免疫反应。
J Neuropathol Exp Neurol. 2013 May;72(5):396-403. doi: 10.1097/NEN.0b013e31828e24ab.
10
Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities.3xTg-AD 小鼠控制性皮质撞击创伤性脑损伤导致急性轴内淀粉样β积聚,并独立加速tau 异常的发展。
J Neurosci. 2011 Jun 29;31(26):9513-25. doi: 10.1523/JNEUROSCI.0858-11.2011.

引用本文的文献

1
Mirodenafil improves cognitive function by reducing microglial activation and blood-brain barrier permeability in ApoE4 KI mice.米罗地那非通过减少载脂蛋白E4基因敲入(ApoE4 KI)小鼠的小胶质细胞活化和血脑屏障通透性来改善认知功能。
Front Aging Neurosci. 2025 May 15;17:1579411. doi: 10.3389/fnagi.2025.1579411. eCollection 2025.
2
Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease.阿尔茨海默病 APPswe/PS1dE9;hAPOE4 小鼠模型的淀粉样蛋白形成的时程特征。
Int J Mol Sci. 2024 May 25;25(11):5754. doi: 10.3390/ijms25115754.
3
Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation.抑制 ACAT 作为阿尔茨海默病的治疗靶点与载脂蛋白 E4 脂质化无关。
Neurotherapeutics. 2023 Jul;20(4):1120-1137. doi: 10.1007/s13311-023-01375-3. Epub 2023 May 8.
4
Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How.载脂蛋白 E 转基因小鼠模型中的阿尔茨海默病病理学:何人、何事、何时、何地、为何、如何。
Neurobiol Dis. 2020 Jun;139:104811. doi: 10.1016/j.nbd.2020.104811. Epub 2020 Feb 20.
5
Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology.阿尔茨海默病患者顶叶皮层的脑壁细胞丢失与认知能力下降和 TDP-43 病理学相关。
Neuropathol Appl Neurobiol. 2020 Aug;46(5):458-477. doi: 10.1111/nan.12599. Epub 2020 Feb 11.
6
Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice.3xTg-AD 小鼠阿尔茨海默病样病理的时空进展。
Aging Cell. 2019 Feb;18(1):e12873. doi: 10.1111/acel.12873. Epub 2018 Nov 28.
7
Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser containing epitope on pathological tau.增强靶向病理性 tau 上含磷酸化 Ser 表位的天然人源抗体的治疗潜力。
Acta Neuropathol Commun. 2018 Jul 12;6(1):59. doi: 10.1186/s40478-018-0562-9.
8
Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.tau 神经病理学发展中的新关键因素:聚焦于 5-脂氧合酶
J Alzheimers Dis. 2018;64(s1):S481-S489. doi: 10.3233/JAD-179931.
9
The Unexpected Role of Aβ1-42 Monomers in the Pathogenesis of Alzheimer's Disease.Aβ1-42 单体在阿尔茨海默病发病机制中的意外作用。
J Alzheimers Dis. 2018;62(3):1241-1245. doi: 10.3233/JAD-170581.
10
EFAD transgenic mice as a human relevant preclinical model of Alzheimer's disease.EFAD转基因小鼠作为阿尔茨海默病的一种与人类相关的临床前模型。
J Lipid Res. 2017 Sep;58(9):1733-1755. doi: 10.1194/jlr.R076315. Epub 2017 Apr 7.

本文引用的文献

1
Intracellular amyloid-beta in Alzheimer's disease.阿尔茨海默病中的细胞内β淀粉样蛋白
Nat Rev Neurosci. 2007 Jul;8(7):499-509. doi: 10.1038/nrn2168.
2
Abeta inhibits the proteasome and enhances amyloid and tau accumulation.β淀粉样蛋白抑制蛋白酶体并增强淀粉样蛋白和tau蛋白的积累。
Neurobiol Aging. 2008 Nov;29(11):1607-18. doi: 10.1016/j.neurobiolaging.2007.04.014. Epub 2007 Jun 1.
3
Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates.载脂蛋白E ε4基因剂量与全脑萎缩率之间的相关性。
Am J Psychiatry. 2007 Jun;164(6):916-21. doi: 10.1176/ajp.2007.164.6.916.
4
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.在转基因小鼠中,通过基因手段增加tau蛋白水平并不能调节β淀粉样蛋白病变的发生或进展。
J Neurochem. 2007 Aug;102(4):1053-63. doi: 10.1111/j.1471-4159.2007.04607.x. Epub 2007 Apr 30.
5
APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD).载脂蛋白E是常染色体显性额颞叶痴呆(IBMPFD)的一种潜在修饰基因。
Genet Med. 2007 Jan;9(1):9-13. doi: 10.1097/gim.0b013e31802d830d.
6
Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons.载脂蛋白E可降低原代神经元中tau激酶和磷酸化tau蛋白的水平。
Mol Neurodegener. 2006 Dec 13;1:18. doi: 10.1186/1750-1326-1-18.
7
The generation and function of soluble apoE receptors in the CNS.中枢神经系统中可溶性载脂蛋白E受体的产生与功能。
Mol Neurodegener. 2006 Oct 24;1:15. doi: 10.1186/1750-1326-1-15.
8
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles.减少可溶性β淀粉样蛋白和tau蛋白(而非仅减少可溶性β淀粉样蛋白)可改善患有斑块和缠结的转基因小鼠的认知衰退。
J Biol Chem. 2006 Dec 22;281(51):39413-23. doi: 10.1074/jbc.M608485200. Epub 2006 Oct 20.
9
Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice.人载脂蛋白E4在神经元或胶质细胞中的表达对双转基因和三转基因小鼠不同脑区的实质和血管淀粉样病理产生不同影响。
Am J Pathol. 2006 Jan;168(1):245-60. doi: 10.2353/ajpath.2006.050752.
10
Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia.APOEε4对额颞叶痴呆行为症状的剂量依赖性效应。
Neurobiol Aging. 2006 Feb;27(2):285-92. doi: 10.1016/j.neurobiolaging.2005.02.005.

从大脑到脉管系统对β淀粉样蛋白分布进行基因改造可改善tau蛋白病变。

Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology.

作者信息

Oddo Salvatore, Caccamo Antonella, Cheng David, LaFerla Frank M

机构信息

Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697-4545, USA.

出版信息

Brain Pathol. 2009 Jul;19(3):421-30. doi: 10.1111/j.1750-3639.2008.00194.x. Epub 2008 Jul 24.

DOI:10.1111/j.1750-3639.2008.00194.x
PMID:18657136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4072242/
Abstract

The inheritance of the epsilon4 allele of the apolipoprotein E (apoE) gene is the major genetic risk factor for developing late-onset Alzheimer disease. In transgenic mice overexpressing amyloid precursor protein (APP), replacing the endogenous mouse apoE gene with the human apolipoprotein E4 (apoE4) gene alters the distribution of amyloid-beta (Abeta) deposits from the brain parenchyma to the vasculature. However, the effects of this distribution on the onset and progression of tau pathology remain to be established. To address this issue, we used a genetic approach to replace the endogenous apoE gene with the human apoE4 allele in the 3xTg-AD mice. We showed that changing Abeta distribution from the parenchyma to the vasculature drastically reduces the tau pathology. The 3xTg-AD mice expressing the human apoE4 gene were virtually depleted of any somatodendritic tau deposits. These data strongly suggest that the somatodendritic tau accumulation is dependent on the parenchyma Abeta deposits.

摘要

载脂蛋白E(apoE)基因的ε4等位基因的遗传是晚发性阿尔茨海默病发生的主要遗传风险因素。在过表达淀粉样前体蛋白(APP)的转基因小鼠中,用人载脂蛋白E4(apoE4)基因替代内源性小鼠apoE基因会使淀粉样β(Aβ)沉积物的分布从脑实质改变为脉管系统。然而,这种分布对tau病理发生和进展的影响仍有待确定。为了解决这个问题,我们采用遗传学方法在3xTg-AD小鼠中用人apoE4等位基因替代内源性apoE基因。我们发现,将Aβ分布从实质改变为脉管系统可显著减少tau病理。表达人apoE4基因的3xTg-AD小鼠几乎没有任何树突体tau沉积物。这些数据有力地表明,树突体tau积累依赖于实质Aβ沉积物。